MOODY’S-ANALYTICS
Moody’s Analytics, a leading provider of financial intelligence, has announced that Greek digital bank, Praxia bank , has selected the Moody’s Analytics suite of regulatory solutions for asset liability management (ALM), IFRS 9, and Basel III compliance.
Praxia bank will use the Moody’s Analytics RiskFoundation™ platform to consolidate and centralize risk management data across its organization using one solution. The award-winning platform delivers a standardized single point of control for performing risk analysis and regulatory reporting tasks, enabling the bank to best utilize its IT investment and execute a consistent enterprise-wide risk management strategy.
Praxia bank will also use the award-winning Moody’s Analytics RiskConfidence™ solution for IFRS 9, and ALM and liquidity risk management. The integrated solution will allow the bank to efficiently cover ALM and liquidity risk.
For Basel III compliance , Praxia bank has selected the RiskAuthority™ software, a comprehensive solution covering data management, regulatory capital calculations, and supervising reporting requirements. Its embedded Basel III calculation ratios and automated workflow processes will enable the bank to deliver efficient and streamlined Basel III compliance while leveraging the automation the solution affords.
“Working with one technology vendor brings significant advantages from an implementation and operations perspective,” said Thanos Papanikolaou, Chief Risk Officer at Praxia bank. “In view of our launch in Greece, we have proudly selected Moody’s Analytics to be our strategic partner. Its platforms allow us to efficiently monitor and manage risk, as well as support the various – and evolving - compliance and regulatory guidelines.”
“As banks globally look for ways to extract value from their regulatory technology investment, there is increasing demand for solutions that enable financial institutions to create synergies between compliance and business optimization,” said Andy Frepp, General Manager at Moody’s Analytics. “We look forward to working with Praxia bank to provide regulatory technology that supports their vision while offering a leaner, more agile approach to risk management.”
Click here to learn more about the Moody’s Analytics suite of regulatory reporting solutions.
About Moody’s Analytics
Moody’s Analytics provides financial
intelligence and analytical tools to help business leaders make better,
faster decisions. Our deep risk expertise, expansive information
resources, and innovative application of technology help our clients
confidently navigate an evolving marketplace. We are known for our
industry-leading and award-winning solutions, made up of research, data,
software, and professional services, assembled to deliver a seamless
customer experience. We create confidence in thousands of organizations
worldwide, with our commitment to excellence, open mindset approach, and
focus on meeting customer needs. For more information about Moody’s
Analytics, visit our website
or connect with us on Twitter
or LinkedIn
.
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.
About Praxia bank
Praxia bank was created in 2018 and is
expected to fully launch within 2019. Praxia bank is a privately-owned
bank with a solid international shareholder structure operating under
the supervision of the Bank of Greece. Deposits are protected by the
Hellenic Deposit & Investment Guarantee Fund. Praxia bank’s executive
team includes talented professionals who bring a wealth of local and
international banking experience and share a common vision: to offer a
sophisticated banking experience that is more humane and at the same
time more digital than ever, to meet the needs of small and medium-sized
businesses as well as retail customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005323/en/
Contact:
TRACEY SCOTT Moody’s Analytics Communications +44.207.772.5207 Moody’s Analytics Media Relations
moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 18:22:00 CEST | Press release
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct
Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 17:45:00 CEST | Press release
Celltrion’s Omlyclo™, the first and only omalizumab biosimilar in Europe, will be commercially available starting in Norway, with subsequent rollouts in European countries Results from the global Phase III clinical trial of Omlyclo™ (CT-P39) for the treatment of chronic spontaneous urticaria (CSU), allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented at a satellite symposium during the 2025 European Academy of Dermatology and Venereology (EADV) Congress Celltrion highlights the strength of its expanding dermatology portfolio with positive clinical results for CT-P55, a biosimilar candidate referencing secukinumab With the launch of Omlyclo™, Celltrion underscores its commitment to advancing innovative and accessible treatments in immunology and dermatology Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereo
Andersen Consulting tilføjer samarbejdsfirmaet Charter18.9.2025 17:14:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine digitale transformationskapaciteter gennem en samarbejdsaftale med Charter, et canadisk konsulentfirma, der er specialiseret i IT-strategi, managed services og applikationslevering. Charter blev grundlagt i 1997 og leverer teknologiprojekter med en forretningsorienteret tankegang og dyb teknisk ekspertise, herunder inden for IT-rådgivning, cloud-infrastruktur, cybersikkerhed, applikationsudvikling, projektlevering og forretningsarkitektur. Charter hjælper traditionelle virksomheder, offentlige institutioner, tjenesteudbydere og mellemstore kunder med implementering, netværksinfrastruktur og kundeorienterede applikationer – der leveres gennem en livscyklus-tilgang fra strategi til udførelse. "Vores mål hos Charter har altid været at fjerne kompleksiteten fra IT og hjælpe organisationer med at bevæge sig fremad med tillid," siger Kelly Michell, præsident for Charter. "Vores samarbejde med Andersen Consulting gør det muligt for os at bringe vores integrere
Andersen Consulting udvider sit udbud inden for cybersikkerhed og teknologi med tilføjelsen af Move18.9.2025 17:06:00 CEST | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Move, der er en førende virksomhed inden for it-infrastruktur, driftstjenester og digitale løsninger til virksomheder. Move befinder sig i Norge og Sverige. Move blev grundlagt i 1989 og leverer konsulentydelser, it-løsninger og driftstjenester. Virksomheden har ekspertise inden for cybersikkerhed, cloud-løsninger, server- og lagringsløsninger, netværkskommunikation og implementering af AI. Move samarbejder med mellemstore og store virksomheder om at designe, implementere og drive sikre, skalerbare og fremtidssikrede it-miljøer. "Dette samarbejde er en spændende mulighed for at skabe endnu større værdi for vores kunder," siger Roald Sannæs, der er administrerende direktør i Move. "Med vores kompetencer og Andersen Consultings globale rækkevidde og ekspertise kan vi levere mere helhedsorienterede løsninger, der hjælper organisationer med at løse nutidens udfordringer og forudse fremtidens muligheder." "Move har opbygget et godt ren
Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 16:40:00 CEST | Press release
The inaugural ranking by TIME, in partnership with Statista, features AMRA as one of the world’s leading health technology companies that are “driving innovation, enhancing accessibility, and contributing to a more effective and sustainable health care system” AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom